Skip to main content
OpenTrials
Completed

NCT Number: NCT02053831

GalaFlex Mesh in Facelift

In this post market study a resorbable mesh (GalaFLEX) will be used to reinforce the lifted and imbricated SMAS along the suture lines and spread the load of the SMAS along a greater surface area. GalaFLEX mesh is comprised of resorbable 4-hydroxybutyrate fibers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ponte Vedra Plastic Surgery, Ponte Vedra Beach, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is able to understand the risks and benefits of participating in the study and must be willing to sign and date the Informed Consent Form for this study approved by the Institutional Review Board (IRB.)
  • Be at least 21 years of age.
  • Be willing and able to comply with the requirements of the protocol.
  • Be willing to refrain from participating in any other investigational interventional study while enrolled in this study.
  • Female subjects must have a negative pregnancy test within the last 24 hours timeline and have no intentions of becoming pregnant during participation in the study, or be sterilized.

Exclusion criteria

  • Subject is unwilling or unable to give written consent to participate in the investigation or unable to comply with the requirements of the protocol.
  • Subject has known severe allergies manifested by a history of anaphylaxis, or history or presence of severe multiple allergies.
  • Subject has any serious skin disease, e.g., Eczema and psoriasis of the face, severe rosacea, scleroderma, local infections and severe acne.
  • Subjects has diabetes, coagulation disorders, connective tissue disorders, lipodystrophy, or other serious systemic disease.
  • Active herpes labialis
  • Subject is infected with HIV and/or received or may receive immunosuppressive therapy over the course of the study (such as rheumatoid arthritis).
  • Received any experimental drug or device within the previous three months.
  • Known alcohol or drug abuser.
  • Female subject who is pregnant or lactating or intending to become pregnant during the period of the study, or who would not use an adequate method of contraception (contraceptive pill, intra-uterine device) for the duration of the study.
  • Possesses any psychological condition, or is under treatment for any condition which, in the opinion of the Investigator and/or consulting physicians(s),would constitute an unwarranted risk.
  • Presents with severe jowling or severe cervical skin redundancy.
  • Subject is currently a smoker or is a prior smoker who quit in the last 12 months.
  • Active abscess or infection
  • Currently involved with claims for, or is accepting, workers compensation
  • Currently engaged in medical malpractice litigation.

Treatment and study plan

Primary outcomes

  1. Physician Satisfaction

    Time frame: 1 year

    Investigator satisfaction will be judged by ease of product use, successful reinforcement, and total time for procedure to be completed.

Secondary outcomes

  1. Patient Satisfaction

    Time frame: 1 year

    Patient satisfaction will be judged by the difference between pre- and post-surgery answers to Quality of Life questionnaires.

Sponsors and collaborators

Lead sponsor

C. R. Bard

Industry

Collaborators

  • Tepha, Inc.

Registry information

Important dates

Study start
2011
Primary completion
2014
Study completion
2014
First posted
Feb 4, 2014
Registry last updated
May 16, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.